339 related articles for article (PubMed ID: 33793836)
1. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.
Lennernäs H; Lindahl A; Van Peer A; Ollier C; Flanagan T; Lionberger R; Nordmark A; Yamashita S; Yu L; Amidon GL; Fischer V; Sjögren E; Zane P; McAllister M; Abrahamsson B
Mol Pharm; 2017 Apr; 14(4):1307-1314. PubMed ID: 28195732
[TBL] [Abstract][Full Text] [Related]
3. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
Guimarães M; Vertzoni M; Fotaki N
AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
[TBL] [Abstract][Full Text] [Related]
4. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
[TBL] [Abstract][Full Text] [Related]
5. In vitro methods to assess drug precipitation in the fasted small intestine - a PEARRL review.
O'Dwyer PJ; Litou C; Box KJ; Dressman JB; Kostewicz ES; Kuentz M; Reppas C
J Pharm Pharmacol; 2019 Apr; 71(4):536-556. PubMed ID: 29956338
[TBL] [Abstract][Full Text] [Related]
6. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
7. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
[TBL] [Abstract][Full Text] [Related]
8. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
[TBL] [Abstract][Full Text] [Related]
9. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
10. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
11. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
[TBL] [Abstract][Full Text] [Related]
12. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
[TBL] [Abstract][Full Text] [Related]
13. Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project.
Abrahamsson B; McAllister M; Augustijns P; Zane P; Butler J; Holm R; Langguth P; Lindahl A; Müllertz A; Pepin X; Rostami-Hodjegan A; Sjögren E; Berntsson M; Lennernäs H
Eur J Pharm Biopharm; 2020 Jul; 152():236-247. PubMed ID: 32446960
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
[TBL] [Abstract][Full Text] [Related]
15. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
[TBL] [Abstract][Full Text] [Related]
16. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.
Jones HM; Parrott N; Ohlenbusch G; Lavé T
Clin Pharmacokinet; 2006; 45(12):1213-26. PubMed ID: 17112297
[TBL] [Abstract][Full Text] [Related]
17. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
18. In-vitro-in-silico investigation of the negative food effect of zolpidem when administered as immediate-release tablets.
Paraiso RLM; Watanabe A; Andreas CJ; Turner D; Zane P; Dressman J
J Pharm Pharmacol; 2019 Nov; 71(11):1663-1676. PubMed ID: 31566757
[TBL] [Abstract][Full Text] [Related]
19. Development of In Vitro Dissolution Testing Methods to Simulate Fed Conditions for Immediate Release Solid Oral Dosage Forms.
Lex TR; Rodriguez JD; Zhang L; Jiang W; Gao Z
AAPS J; 2022 Mar; 24(2):40. PubMed ID: 35277760
[TBL] [Abstract][Full Text] [Related]
20. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
